Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Rhea-AI Summary
Intensity Therapeutics (Nasdaq: INTS) announced two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX, taking place December 9–12, 2025.
Presentation 1: "Accelerating an Anthracycline-Free Future" — poster #801 (PS4-10-15) presented by Lewis Bender on Dec 11, 2025 at 5:00 PM CT. Presentation 2: INVINCIBLE-4-SAKK 66/22 Phase II early observations on intratumoral INT230-6 — poster #1589 (PS5-01-04) presented by Andreas Müller on Dec 12, 2025 at 12:00 PM CT.
Both presentations describe clinical and early clinical observations for INT230-6 and potential anthracycline‑sparing combinations in breast cancer therapy.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, INTS gained 12.96%, reflecting a significant positive market reaction. Argus tracked a peak move of +39.4% during that session. Argus tracked a trough of -4.0% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $32M at that time. Trading volume was elevated at 2.8x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
INTS gained 4.3% while selected biotech peers were mixed but generally positive, including ERNA at +18.4%, SNSE at +11.66%, and LYRA at +4.17%, with smaller moves in MBRX and BOLT. No peers appeared in the momentum scanner.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 05 | Listing compliance | Neutral | +10.2% | Nasdaq granted 180-day extension to regain $1.00 minimum bid compliance. |
| Dec 04 | Conference presentations | Positive | +13.0% | Announcement of two SABCS posters highlighting INT230-6 clinical observations. |
| Nov 06 | Earnings and update | Negative | -14.9% | Q3 2025 results, clinical pauses, and funding-dependent plans for programs. |
| Oct 31 | Equity offering | Negative | -44.7% | Pricing of 5,000,000-share registered direct offering for $4.0M gross proceeds. |
| Oct 30 | Clinical results | Positive | +394.6% | Publication of phase 1/2 INT230-6 data with 75% disease control and survival data. |
Recent news with clinical or conference focus has coincided with positive price reactions, while equity offerings and financing updates have coincided with sharp declines.
This announcement of SABCS presentations follows several months of financing, clinical, and listing-compliance developments. A late October eBioMedicine publication of INT230-6 data saw a +394.57% move, while a $4.0 million registered direct offering the next day coincided with a -44.68% reaction. Q3 2025 results and a corporate update on Nov 6, 2025 were followed by a -14.86% move, reflecting funding and program pauses. More recently, a Nasdaq minimum bid-price extension on Dec 5, 2025 and this SABCS presentation news saw double‑digit percentage gains.
Market Pulse Summary
The stock surged +13.0% in the session following this news. A strong positive reaction aligns with prior instances where clinical or conference-related updates for INT230-6 coincided with notable gains, such as the eBioMedicine publication that preceded a +394.57% move. However, history also shows sharp declines following equity offerings and financing updates, including a -44.68% move after an October 2025 offering. Investors reviewing such a surge have had to weigh enthusiasm for breast cancer data visibility against the company’s reliance on external funding and prior volatility.
Key Terms
anthracycline medical
intratumoral medical
neoadjuvant medical
triple negative breast cancer medical
phase II medical
randomized clinical trial medical
AI-generated analysis. Not financial advice.
Presentations:
Title: | Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations |
Date: | Thursday, December 11, 2025 |
Time: | 5 p.m. – 6:30 p.m. CT |
Abstract/Poster: | #801 Poster PS4-10-15 |
Presenting author: | Lewis Bender, M.S. M.A. M.B.A., Intensity Therapeutics |
Title: | Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Clinical Trial |
Date: | Friday, December 12, 2025 |
Time: | 12 p.m. – 1:30pm CT |
Abstract/Poster: | #1589 PS5-01-04 |
Presenting author: | Andreas Müller, M.D., Swiss Cancer Institute |
About INT230-6
INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule ("SHAO") that non-covalently conjugates to the two payload drugs, facilitating the dispersion of potent cytotoxic drugs throughout tumors and allowing the active agents to diffuse into cancer cells. These agents remain in the tumor, resulting in a favorable safety profile. In addition to local disease control and direct tumor killing, INT230-6 causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression, which often occurs with systemic chemotherapy.
About Intensity Therapeutics
Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies that enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the standard of care ("SOC") with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, formerly SAKK, now the Swiss Cancer Institute (the "INVINCIBLE-4 Study") (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response ("pCR") is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com or review our SEC filings.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; our potential inability to satisfy the Nasdaq Capital Market's requirements for continued listing and be subject to delisting; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company's subsequent SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor Relations Contact:
Justin Kulik
CORE IR
coreirteam@coreir.com
(516) 222-2560
Media Contact:
Matt Cossel
CORE IR
pr@coreir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-announces-two-presentations-at-the-upcoming-2025-san-antonio-breast-cancer-symposium-302632674.html
SOURCE Intensity Therapeutics Inc.
FAQ
When will Intensity Therapeutics present at SABCS 2025 (INTS)?
What topics will Intensity Therapeutics (INTS) cover at SABCS 2025?
What are the poster IDs for Intensity Therapeutics at SABCS 2025?
Who are the presenters for Intensity Therapeutics (INTS) at SABCS 2025?
What clinical trial is discussed in Intensity Therapeutics' SABCS poster on Dec 12, 2025?
How can investors find the Intensity Therapeutics SABCS presentations (INTS)?
